Literature DB >> 30006177

4-(Phenoxy) and 4-(benzyloxy)benzamides as potent and selective inhibitors of mono-ADP-ribosyltransferase PARP10/ARTD10.

Sudarshan Murthy1, Jenny Desantis2, Patricia Verheugd3, Mirko M Maksimainen1, Harikanth Venkannagari1, Serena Massari2, Yashwanth Ashok1, Ezeogo Obaji1, Yves Nkizinkinko1, Bernhard Lüscher3, Oriana Tabarrini2, Lari Lehtiö4.   

Abstract

Human Diphtheria toxin-like ADP-ribosyltranferases (ARTD) 10 is an enzyme carrying out mono-ADP-ribosylation of a range of cellular proteins and affecting their activities. It shuttles between cytoplasm and nucleus and influences signaling events in both compartments, such as nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) signaling and S phase DNA repair. Furthermore, overexpression of ARTD10 induces cell death. We recently reported on the discovery of a hit compound, OUL35 (compound 1), with 330 nM potency and remarkable selectivity towards ARTD10 over other enzymes in the human protein family. Here we aimed at establishing a structure-activity relationship of the OUL35 scaffold, by evaluating an array of 4-phenoxybenzamide derivatives. By exploring modifications on the linker between the aromatic rings, we identified also a 4-(benzyloxy)benzamide derivative, compound 32, which is potent (IC50 = 230 nM) and selective, and like OUL35 was able to rescue HeLa cells from ARTD10-induced cell death. Evaluation of an enlarged series of derivatives produced detailed knowledge on the structural requirements for ARTD10 inhibition and allowed the discovery of further tool compounds with submicromolar cellular potency that will help in understanding the roles of ARTD10 in biological systems.
Copyright © 2018 Elsevier Masson SAS. All rights reserved.

Entities:  

Keywords:  ADP-Ribosylation; ARTD; Inhibitor; PARP; Structure-activity relationship

Mesh:

Substances:

Year:  2018        PMID: 30006177     DOI: 10.1016/j.ejmech.2018.06.047

Source DB:  PubMed          Journal:  Eur J Med Chem        ISSN: 0223-5234            Impact factor:   6.514


  9 in total

Review 1.  Medicinal Chemistry Perspective on Targeting Mono-ADP-Ribosylating PARPs with Small Molecules.

Authors:  Maria Giulia Nizi; Mirko M Maksimainen; Lari Lehtiö; Oriana Tabarrini
Journal:  J Med Chem       Date:  2022-05-24       Impact factor: 8.039

Review 2.  Research Progress on Mono-ADP-Ribosyltransferases in Human Cell Biology.

Authors:  Yujie Gan; Huanhuan Sha; Renrui Zou; Miao Xu; Yuan Zhang; Jifeng Feng; Jianzhong Wu
Journal:  Front Cell Dev Biol       Date:  2022-05-16

3.  Rational design of selective inhibitors of PARP4.

Authors:  Ilsa T Kirby; Ashley Person; Michael Cohen
Journal:  RSC Med Chem       Date:  2021-10-04

4.  Synthesis, molecular docking, and cytotoxicity of quinazolinone and dihydroquinazolinone derivatives as cytotoxic agents.

Authors:  Fahimeh Taayoshi; Aida Iraji; Ali Moazzam; Meysam Soleimani; Mehdi Asadi; Keyvan Pedrood; Mosayeb Akbari; Hafezeh Salehabadi; Bagher Larijani; Neda Adibpour; Mohammad Mahdavi
Journal:  BMC Chem       Date:  2022-05-18

5.  Integrating DNA-encoded chemical libraries with virtual combinatorial library screening: Optimizing a PARP10 inhibitor.

Authors:  Mike Lemke; Hannah Ravenscroft; Nicole J Rueb; Dmitri Kireev; Dana Ferraris; Raphael M Franzini
Journal:  Bioorg Med Chem Lett       Date:  2020-08-05       Impact factor: 2.823

6.  ADP-ribosylation: from molecular mechanisms to human disease.

Authors:  Nicolas C Hoch; Luis M Polo
Journal:  Genet Mol Biol       Date:  2019-12-13       Impact factor: 1.771

Review 7.  Mono(ADP-ribosyl)ation Enzymes and NAD+ Metabolism: A Focus on Diseases and Therapeutic Perspectives.

Authors:  Palmiro Poltronieri; Angela Celetti; Luca Palazzo
Journal:  Cells       Date:  2021-01-11       Impact factor: 6.600

8.  Preclinical Lead Optimization of a 1,2,4-Triazole Based Tankyrase Inhibitor.

Authors:  Jo Waaler; Ruben G G Leenders; Sven T Sowa; Shoshy Alam Brinch; Max Lycke; Piotr Nieczypor; Sjoerd Aertssen; Sudarshan Murthy; Albert Galera-Prat; Eddy Damen; Anita Wegert; Marc Nazaré; Lari Lehtiö; Stefan Krauss
Journal:  J Med Chem       Date:  2020-06-23       Impact factor: 7.446

9.  Evaluation of 3- and 4-Phenoxybenzamides as Selective Inhibitors of the Mono-ADP-Ribosyltransferase PARP10.

Authors:  Patricia Korn; Arno Classen; Sudarshan Murthy; Riccardo Guareschi; Mirko M Maksimainen; Barbara E Lippok; Albert Galera-Prat; Sven T Sowa; Catharina Voigt; Giulia Rossetti; Lari Lehtiö; Carsten Bolm; Bernhard Lüscher
Journal:  ChemistryOpen       Date:  2021-06-19       Impact factor: 2.630

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.